Phase 2 N=4 Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Determine Maximum Tolerated Dose of TRC105 in Combination With Capecitabine — 0; 3; 0; 3 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=197 CASA: Care and Support Access in HIV Disease
HIV/AIDS
Primary: Mental Health: Rosenberg Self-Esteem Scale — 3.2; 3.2; 3.2; 3.1 [Units on a scale] — p=0.400
Phase 2 N=12 Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
Acute Lymphoblastic Leukemia (ALL) · Acute Myelogenous Leukemia (AML) · Myelodysplastic Syndrome (MDS)
Primary: Acute Toxicity Associated With the Infusion of NiCord — 0 Participants
Phase 2 N=420 A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris
Acne Vulgaris
Primary: Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12 — -10.5; -11.0; -14.6; -14.5 Lesions — p=0.0006
Phase 2 N=19 Effects of Sildenafil on CFTR-dependent Ion Transport Activity
Cystic Fibrosis
Primary: Change in Sodium Conductance by Nasal Potential Difference (NPD) — -0.70; 1.81 mV
Phase 2 N=30 Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma
Lymphoma
Primary: Number of Participants With Grade 3-5 Adverse Events — 6 Participants
Phase 3 N=330 A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001
Glabellar Frown Lines
Primary: Percentage of Participants With a ≥2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and Subject — 67.5; 1.2 percentage of…
Phase 2 N=16 Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)
Phenylketonuria
Primary: Blood Phenylalanine Concentration — 1482.1; 1566.0 umol/L
Phase 2 N=9 Role of Exenatide in Type 1 Diabetes
Type 1 Diabetes
Primary: Mean Plasma Glucose Area Under the Curve (AUC) for Blood Glucose Concentration in the Exenatide 1.25 mcg or Exenatide 2.5 mcg Treated Groups Along With Insulin, Compared…
Phase 2 N=43 Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant
Influenza
Primary: Flu Antibody Titers — 10.65; 10.35; 31.09; 10.35 Titers
N/A N=10 The Virtual Visit for Women With Gestational Diabetes
Diabetes, Gestational
Primary: Compliance With Requirements for Frequency of Glucose Measures — 3.1 number of glucose checks per pt per day
Phase 3 N=51 Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study
Opioid Use Disorder · Alcohol Use Disorder
Primary: Number of Participants With Successful Initiation of Treatment Within 4 Weeks of Randomization — 25; 17 Participants
N/A N=184 A Comparison of the First Attempt Success Rate of Cannulation Between the Accuvein Apparatus and Standard Technique
Procedural Complication
Primary: First Attempt Success Rates With the AccuVein 300 Device Versus Standard Method — 92; 92 Participants
Early Phase 1 N=37 Biomarker Study in Participants With Migraine
Migraine Disorders
Primary: The Capsaicin-Induced Dermal Blood Flow (DBF) — 606.1; 599.5; 689.2 Flux mean
Phase 4 N=22 Targeting Right Ventricle in Pulmonary Hypertension Gilead
Pulmonary Hypertension
Primary: Absolute Change From Baseline Right Ventricular Ejection Fraction (the Unit is Percentage) — 7.56; -3.99 percentage